Volume 2, Issue 2

Asthma Management: The Current State of the Art in Early 2022

In this issue:

Managing patients with asthma continues to grow more complex. Two key guidelines have recently been updated. Where do their recommendations concur? Where do they differ, and why? Where do the newer biologic agents fit into evolving treatment paradigms? Which patients are likely to benefit, and in which are specific biologics inappropriate?

These are some of the questions we discuss with Dr. Ashraf Fawzy, from the Division of Pulmonology and Critical Care at Johns Hopkins University, in this ePulmonology Review podcast.

Learning objectives:

  • Discuss the differences between the NHLBI and GINA guideline strategies for managing mild asthma. 
  • Explain the indications for biologic therapy in severe asthma and the rationale for prescribing specific biologic therapies. 

Author:

Ashraf Fawzy, MD, MPH
Ashraf Fawzy, MD, MPH

Assistant Professor of Medicine
Division of Pulmonary and Critical Care
Johns Hopkins University
Baltimore, Maryland

Program Directors:

Gregory B. Diette, MD

Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christine Smith, RN, MSN

Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
Baltimore, Maryland

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: January 31, 2022
Expiration date: January 30, 2024